Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 1
2003 3
2004 4
2005 5
2006 1
2008 1
2010 1
2011 1
2012 1
2014 3
2015 2
2016 1
2017 4
2018 2
2019 1
2020 4
2022 10
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
Kaabi NA, Yang YK, Liang Y, Xu K, Zhang XF, Kang Y, Jin YQ, Hou JW, Zhang J, Yang T, Hussein S, ElDein MS, Lei ZH, Zhang H, Shao S, Liu ZM, Liu N, Zheng X, Su JG, Yang SS, Cong X, Tan Y, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Shen FJ, Wu JJ, Han ZB, Du LF, Tang F, Chen S, Ma ZJ, Zheng F, Hou YN, Li XY, Li X, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: shen fj. Signal Transduct Target Ther. 2023 Jan 3;8(1):20. doi: 10.1038/s41392-022-01295-2. Signal Transduct Target Ther. 2023. PMID: 36596779 Free PMC article. Clinical Trial.
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2.
Liang Y, Zhang J, Yuan RY, Wang MY, He P, Su JG, Han ZB, Jin YQ, Hou JW, Zhang H, Zhang XF, Shao S, Hou YN, Liu ZM, Du LF, Shen FJ, Zhou WM, Xu K, Gao RQ, Tang F, Lei ZH, Liu S, Zhen W, Wu JJ, Zheng X, Liu N, Chen S, Ma ZJ, Zheng F, Ren SY, Hu ZY, Huang WJ, Wu GZ, Ke CW, Li QM. Liang Y, et al. Among authors: shen fj. Cell Discov. 2022 Feb 15;8(1):17. doi: 10.1038/s41421-022-00383-5. Cell Discov. 2022. PMID: 35169113 Free PMC article.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: shen fj. Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2. Signal Transduct Target Ther. 2022. PMID: 35665745 Free PMC article. Clinical Trial.
49 results